Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 5,286 matching trials from the live ClinicalTrials.gov search.
Conditions
Narcolepsy
Interventions
SUVN-G3031, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more
Conditions
Lung Cancer
Interventions
Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
217
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Conditions
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 60 Years
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
404
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more
Conditions
Acute Pancreatitis
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Conditions
Glioblastoma, Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
390
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Study of ALK-001 in Geographic Atrophy

NCT03845582
Conditions
Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
Interventions
ALK-001 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Lakewood, Colorado + 20 more
Conditions
Reasoning Training
Interventions
Telehealth Reasoning Training
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Chronic Low Back Pain
Interventions
Bupivacaine TTS (Bupivacaine Patch), Placebo patch
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 70 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Tempe, Arizona • La Mesa, California • Torrance, California + 18 more
Conditions
Cystic Fibrosis
Interventions
CF with culturable NTM
Procedure
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 4 Interventional Results available

RNS® System LTT Study

NCT00572195
Conditions
Epilepsy
Interventions
RNS® System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
33
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 29 more
Conditions
Duchenne Muscular Dystrophy
Interventions
Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
Conditions
Acute Kidney Injury (AKI)
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
35 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Clearwater, Florida + 23 more
Active, not recruiting Phase 2 Interventional

Use of CBD in the Treatment of Anxiety

NCT06672666
Conditions
Anxiety, Generalized Anxiety Disorder, Sleep Problems
Interventions
Hemp Derived Cannabidiol Extract, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Pharmacokinetics
Interventions
Low furanocoumarin hybrid grapefruit juice, Regular grapefruit juice, Water (control)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

NCT04505722
Conditions
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Interventions
Ad26.COV2.S, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
44,325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
117
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 77 more
Conditions
Duchenne Muscular Dystrophy
Interventions
RGX-202
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
1 Year and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
19
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 16 more
Conditions
Osteoarthritis of the Knee
Interventions
Lidoderm, Celecoxib
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
20
States / cities
Hueytown, Alabama • Mesa, Arizona • Oro Valley, Arizona + 17 more
Conditions
Pain, Postoperative
Interventions
single-arm study group
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Congestive Heart Failure
Interventions
MyoCell, Hypothermosol
Biological · Procedure
Lead sponsor
Bioheart, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Iza-bren, Carboplatin, Cisplatin, Pemetrexed, Amivantamab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
28
States / cities
Irvine, California • Orange, California • Edwards, Colorado + 22 more
Conditions
Hepatocellular Cancer
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
52
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

taVNS for Letter Learning in Dyslexia

NCT06127550
Conditions
Dyslexia
Interventions
active taVNS, sham taVNS
Device
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida